FDA Historical Calendar

TickerCurrent price52 hi52 loProductIndicationPDUFA dateDecisionNotes
PGNX4.727.453.10Subcutaneous RELISTORChronic pain9/29/2014PDUFA September 29 2014 for sNDA of Subcutaneous RELISTOR for
SLXP140.42172.9870.64Subcutaneous RELISTORChronic pain9/29/2014PDUFA September 29 2014 for sNDA of for chronic pain
ALIM6.028.441.76IluvienDiabetic macular edema9/26/2014Approved Sept 26 2014
PSDV4.235.452.28IluvienDiabetic macular edema9/26/2014Approved Sept 26 2014
AUXL31.3433.0016.71AvanafilErectile dysfunction9/20/2014ApprovedApproved 9/18/2014 - sNDA to change label allowing use 15 minutes before sexual activity.
VVUS3.4110.293.13AvanafilErectile dysfunction9/20/2014ApprovedApproved 9/18/2014 - sNDA to change label allowing use 15 minutes before sexual activity.
NKTR13.1515.348.87NaloxegolOpioid-induced constipation (OIC)9/16/2014ApprovedApproved Sept 16 2014
SLXP140.42172.9870.64Budesonide foamModerate ulcerative proctitis or proctosigmoiditis 9/15/2014Tentative approvalTentative approval granted September 15 2014 pending patent issues
HALO9.1518.186.88HYQVIASubcutaneous treatment for patients with primary immunodeficiency (PI)ApprovedApproved Sept 12 2014
OREX4.397.823.11ContraveObesity9/11/2014ApprovedApproved September 11 2014
MDVN101.87103.8854.37XTANDICancer - mCRPC who have not received chemotherapy9/17/2014ApprovedApproved Sept 10 2014
KERX16.7318.4810.01ZerenexHyperphosphatemia9/7/2014ApprovedApproved Sept 5 2014
LGND53.9780.4241.99PromactaAplastic AnemiaApproved Approved August 27 2014
MDCO21.9441.2819.92OritavancinABSSSI8/6/2014ApprovedApproved under priority review
PCYC123.68154.8982.51Ibrutinib Deletion 17pApprovedApproved July 29 2014
PCYC123.68154.8982.51Ibrutinib Cancer - Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL)ApprovedApproved July 29 2014
ACRX6.7813.645.22ZalvisoPost-operative pain following open abdominal surgery and hip or knee replacement surgery7/27/2014CRLCRL Jul 26 2014
EGRX12.3416.449.16RyanodexMalignant hyperthermia7/22/2014Approved
SLXP140.42172.9870.64RUCONESTHereditary angioedema (HAE)7/16/2014Approved Partnered with Dutch company Pharming
ANAC28.3628.7311.34TavaboroleOnychomycosis7/29/2014ApprovedApproved July 8 2014
SPPI7.7010.326.36BelinostatCancer - Peripheral T-Cell Lymphoma8/9/2014ApprovedApproved two months early under accelerated approval program.
EGRX12.3416.449.16EP-3101 (bendamustine RTD) Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma7/6/2014Approved - tentativeTentative approval (July 2 2014) will convert to a final approval subject to patent litigation with Teva Pharmaceutical
FLML12.7715.965.30VAZCULEP (phenylephrine hydrochloride)Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia8/6/2014ApprovedApproved June 30 2014. PDUFA of August 6 was for a resubmission following CRL
NPSP26.9339.6821.60GATTEXShort Bowel Syndrome 7/28/2014ApprovedsNDA - seeking additions to label
MNKD5.7311.483.80AFREZZA Type 1/2 diabetes7/15/2014ApprovedApproved June 27 2014
CBST70.9382.1258.50Tedizolid phosphateAcute bacterial skin and skin structure infections (ABSSSI)6/22/2014Approved Approved June 20 2014
NAVB1.362.251.11LymphoseekHead and Neck Cancer6/16/2014ApprovedApproved Jun 13 2014
BDSI16.6218.484.16BEMA Buprenorphine/Naloxone (BNX) - BUNAVAILOpioid dependence6/7/2014ApprovedApproved June 7 2014
OMER12.2118.806.92OmidriaCataract surgery6/1/2014Approved Approved June 2 2014
TRLPF0.430.850.29Loading...PDUFA5/28/2014PDUFA date February 28 2014, extended to May 28 2014, for bioadhesive intranasal gel testosterone product (CompleoTRT)
QRXPY0.094.350.06MOXDUOModerate to severe acute pain5/25/2014CRL
DRTX23.9824.339.15DalbavancinAcute bacterial skin and skin structure infections (ABSSSI)5/26/2014ApprovedApproved May 23 2014
FLML12.7715.965.30??????4/28/2014CRLCRL April 28 2014
MDCO21.9441.2819.92CangrelorReduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).4/30/2014CRLCRL April 30 2014
POZN8.759.905.35PA32540 and PA8140Cardiovascular patients at risk for developing aspirin-associated gastric ulcers4/25/2014CRLCRL Apr 25 2014 - manufacturing deficiencies
TSX:PLBImpavidoTropical disease leishmaniasis3/19/2014ApprovedApproved Mar 19
BMY53.6357.4946.30Eliquis To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
PFE29.1132.9627.51EliquisTo Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
ENDP65.0482.1643.12AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadism3/28/2014ApprovedApproved March 6 2014
AZN70.1282.6852.08MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
BMY53.6357.4946.30MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
CHTPNORTHERA Neurogenic Orthostatic HypotensionApprovedApprovedApproved one day late due to snow. Acquired by Lundbeck
BMRN81.0384.2555.04Vimizim (GALNS)(MPS IVA) Morquio A Syndrome2/28/2014Approved Early approval. Was under priority review
DRRX1.392.691.25PosidurPost-operative pain relief 2/12/2014CRL
PCYC123.68154.8982.51Ibrutinib Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy2/28/2014ApprovedApproved Feb 12 2014
VNDA11.1119.255.70HETLIOZ (tasimelteon)Non-24-Hour Sleep-Wake Disorder1/31/2014Approved
VRX129.13153.10102.60Retin-A Micro (tretinoin) Gel microsphere 0.08% Acne vulgarisApprovedsNDA
AMAG33.2934.5916.49FerahemeIron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) to all adult patients with IDA who have failed or could not tolerate oral iron treatment1/21/2014CRLOriginal PDUFA date delayed
NRIFF4.695.201.54Pennsaid 2%Pain of osteoarthritis of the knee2/7/2014ApprovedApproved Jan 17 2014
AZN70.1282.6852.08FARXIGA (dapagliflozin) tablets Adult patients with type 2 diabetesApproved
BMY53.6357.4946.30FARXIGA (dapagliflozin) tabletsAdult patients with type 2 diabetesApproved
GSK45.7956.7341.91Mekinist (trametinib) and Tafinlar (dabrafenib)Unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutationsApprovedAccelerated approval based on Phase 2 trial. Approval coningent on Phase 3 trial outcome
MRK57.6161.3344.62ISENTRESS for oral suspensionHIV-1 infected infants and childrenApproved
AZN70.1282.6852.08Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
BMY53.6357.4946.30Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
SNY54.0257.4247.06LemtradaRelapsing forms of multiple sclerosis.CRLCRL 29/12/13
UTHR132.35136.9381.60Oral treprostinilPulmonary arterial hypertension (PAH)2/16/2014ApprovedApproved Dec 20 2013. Early approval following previous extension
THRX17.0832.9115.76UMEC/VI (62.5/25mcg and 125/25mcg doses) ANORO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)12/18/2013ApprovedApproved Dec 18 2013
JNJ103.13108.7786.09Canagliflozin and immediate-release metforminAdults with type 2 diabetesCRL
GILD110.71111.4763.50Sovaldi (Sofosbuvir)HCV6/12/2013Approved
AUXL31.3433.0016.71XIAFLEXPeyronie’s6/12/2013ApprovedApproved Dec 6 2013
PCYC123.68154.8982.51Ibrutinib versus temsirolimus - RAY (MCL3001)Cancer - relapsed or refractory MCL mantle cell lymphoma2/28/2013Approved Approved Nov 13 2013, 3 months early. Was under priority review
ZGNX1.275.191.07Zohydro ERModerate to severe painApprovedApproved Oct 25 2013. Decision was delayed by several months
AGN184.21192.9888.34JUVÉDERM VOLUMA XCAge-related volume loss in the cheek area in adults over the age of 21ApprovedApproved Oct 23 2013
ALIOF113.37129.2576.79Macitentan (Opsumit)Pulmonary arterial hypertension10/18/2013ApprovedApproved Oct 18 2013
ALIM6.028.441.76IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
PSDV4.235.452.28IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
ATRS2.035.011.82OTREXUPRheumatoid arthritis (RA)10/14/2013ApprovedApproved Oct 14 2013
DCTH1.746.721.70CHEMOSAT systemCancer - unresectable metastatic ocular melanoma in the liver9/13/2013CRL CRL Sept 13 2013
CELG103.24103.3166.85ABRAXANEMetastatic pancreatic cancer9/21/2013ApprovedApproved Sep 6 2013
QRXPY0.094.350.06MOXDUOModerate to severe acute pain8/26/2013CRLCRL Aug 2013. Expects to resubmit 4Q 2013. Expects Adcom meeting
SUPN7.5111.476.12Trokendi XR SPN-538EpilepsyApprovedApproved Aug 19 2013
JNJ103.13108.7786.09SIMPONI ARIARheumatoid ArthritisApprovedApproved Jul 18 2013
MRK57.6161.3344.62Suvorexant tabletsInsomniaCRLAdcom May 22 2013. 13-3 positive vote. CRL received Jul 1 2013
GSK45.7956.7341.91Dolutegravir - ViiV HealthcareHIV8/17/2013ApprovedPDUFA Aug 12 under priority review.
JNJ103.13108.7786.09XARELTO (rivaroxaban)Stent Thrombosis in Patients with Acute Coronary SyndromeCRLCRL issued Jun 28 2013
THRX17.0832.9115.76VIBATIV (telavancin hydrochloride) for injectionHospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)ApprovedApproved Jun 21 2013
AMGN147.26148.14108.20XGEVACancer - Giant Cell Tumor Of BoneApprovedApproved 6/13/13
AVEO0.962.350.85TivozanibCancer - advanced renal cell carcinoma7/28/2013CRLNegative 1-13 vote at Adcom meeting May 2 2013.Early CRL Jun 10 2013
CELG103.24103.3166.85REVLIMIDCancer - relapsed/refractory mantle cell lymphomaApproved Approved Jun 5 2013 under priority review
FLML12.7715.965.30Bloxiverz (neostigmine methylsulfate)Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery5/31/2013ApprovedApproved Jun 3 2013
DEPO15.1015.707.09SEFELSAHot flashes5/31/2013CRLCRL May 31 2013
ENDP65.0482.1643.12AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadismCRLCRL issued May 30 2013. Expects to respond 3Q 2013
GSK45.7956.7341.91DabrafenibCancer - melanoma6/3/2013Approved Approved May 29 2013
GSK45.7956.7341.91TrametinibCancer - melanoma6/3/2013ApprovedApproved May 29 2013
VRX129.13153.10102.60EfinaconazoleOnychomycosis5/24/2013CRLCRL May 28 2013
JNJ103.13108.7786.09SIMPONI (golimumab) ulcerative colitis (UC)ApprovedApproved May 16
THRX17.0832.9115.76BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
GSK45.7956.7341.91BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
BMY53.6357.4946.30SUSTIVA® (efavirenz)HIV-1ApprovedsNDA approved May 3 2013
MRK57.6161.3344.62LIPTRUZET (ezetimibe and atorvastatin)LDL CholesterolApprovedApproved May 3 2013
SHPG194.49264.98129.58Vyvanse® (lisdexamfetamine dimesylate) Children and Adolescents with ADHD5/1/2013ApprovedApproved May 1 2013
TTNP0.470.960.45ProbuphineOpioid dependence4/30/2013CRLCRL issued midnight Apr 30
RPTP10.9817.727.12DR CysteamineCystinosis4/30/2013ApprovedApproved Apr 30, 2013.
GILD110.71111.4763.50ElvitegravirHIV4/27/2013CRLCRL Apr 29 2013
GILD110.71111.4763.50CobicistatHIV4/28/2013CRLCRL Apr 29 2013
SCMP8.3111.005.80Amitiza/ LubiprostoneOpioid-induced bowel dysfunction4/24/2013ApprovedApproved Apr 23 2013
NVS90.1595.5076.36Simbrinza(TM) SuspensionGlaucomaApprovedApproved Apr 19 2013
JNJ103.13108.7786.09InvokanaType 2 diabetes3/31/2013ApprovedApproved Mar 29 2013
APPA7.93APF530Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)3/27/2013CRLCRL Mar 28 2013. Changed ticker to HRTX
UTHR132.35136.9381.60Treprostinil diolamine extended release tablets (oral treprostinil)Pulmonary arterial hypertension3/31/2013CRLCRL Mar 25, 6 days early
NAVB1.362.251.11LymphoseekLymphatic-tissue tracing agent4/30/2013Approved Approved Mar 13 2013. 7 weeks early.
JNJ103.13108.7786.09XARELTOReduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS)3/5/2013CRLCRL March 5 2013
ONXXStivargaMetastatic and/or unresectable gastrointestinal stromal tumors (GIST)2/25/2013ApprovedApproved Feb 25 2013. Acquired by Amgen.
DVAX1.622.141.10HEPLISAVHepatitis B2/24/2013CRLCRL Feb 25 2013. Hopes to meet with FDA by mid April to discuss CRL
IMGN8.7518.197.70KadcylaCancer - 2nd-line HER2+ Metastatic Breast Cancer2/26/2013ApprovedApproved Feb 22 2013 - under priority review
NVS90.1595.5076.36Zortress (everolimus)Prevent organ rejection in adult liver transplant patientsApprovedApproved Feb 15 2013
CELG103.24103.3166.85PomalystCancer - Multiple Myeloma2/10/2013ApprovedApproved Feb 8 2013
HEB0.280.550.19Ampligen CFS2/4/2013CRLCRL Feb 4 2012. Resubmission. More trials required. Intends to appeal
HPTX23.8832.9818.97RavictiUrea cycle disorders1/22/2013ApprovedApproved Feb 1 2013. FDA had advised company of delay
FURX104.77121.9732.05AlogliptinDiabetes - Type 21/27/2013Approved NDA resubmitted July 27 2012, following CRL. Approved Jan 25 2013
IPXL27.8031.0419.67IPX066Parkinson's 1/21/2013CRLCRL January 21 2013
PATHZecuity Migraine1/17/2013ApprovedApproved Jan 17 2013. Acquired by TEVA.
SNTSBudesonideUCERIS (Budesonide)Ulcerative colitis disease1/16/2013ApprovedApproved Jan 14 2013, two days early. Acquired by Salix.
AEGR30.66101.0026.25LomitapideHomozygous familial hypercholesterolemia (HoFH)1/6/2013ApprovedEarly approval Dec 24 2012
ALXA2.275.931.99Staccato loxapine (ADASUVE). Schizophrenia12/21/2012Approved
NPSP26.9339.6821.60GattexShort bowel syndrome or SBS12/30/2012ApprovedPDUFA date was Dec 30 2012. Early approval on Dec 21
ARIA5.839.832.15Oral ponatinibCancer - chronic myeloid leukemia, acute lymphoblastic leukemia3/27/2013ApprovedPDUFA March 27 2013. Early approval Dec 14 2012 under priority review
EXEL1.698.411.35CabozantinibCancer - Medullary thyroid 11/29/2012ApprovedApproved Nov 29 2012 under priority review
LGND53.9780.4241.99Promacta/RevoladeThrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C11/30/2012ApprovedApproved Nov 19 2012 under priority review, 11 days prior to PDUFA date
CRTXCRTX 080Hyponatremia10/29/2012CRLAdditional clinical and non-clinical information required. Acquired by Chiesi Farmaceutici S.p.A
SUPN7.5111.476.12OxtellarEpilepsy10/22/2012Approved
NAVB1.362.251.11LymphoseekLymphatic-tissue tracing agent9/10/2012CRL3rd party manufacturing deficiencies cited
MDVN101.87103.8854.37MDV3100Cancer - prostate 2nd line8/31/2012Approved Early approval decision by 3mths approx. Was under priority review
TLON0.161.830.13Marqibo2nd line adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)8/12/2012Approved Approved 8/9/2012
HALO9.1518.186.88HyQPrimary immunodeficiency diseaseCRL
PGNX4.727.453.10Subcutaneous RELISTORchronic pain7/27/2012CRLPrice shown is for PGNX. Partnered with SLXP
AMRN0.942.750.94Vascepa Elevated triglyceride levels7/26/2012Approved
HZNP12.3418.303.70LODOTRA (RAYOS)Rheumetoid Arthritis7/26/2012Approved
ONXXCarfilzomibMultiple myeloma7/20/2012ApprovedAcquired by Amgen.
VVUS3.4110.293.13QnexaObesity7/18/2012Approved
ARNA4.177.973.26LorcaserinObesity6/27/2012Approved
QRX0.020.950.02MOXDUOModerate to severe acute pain6/26/2012CRL
RGEN24.1124.6810.10RG1068Detection of pancreatic duct abnormalities6/22/2012CRL
XNPT6.727.203.14HorizantPostherpetic Neuralgia6/9/2012Approved
ARIA5.839.832.15RidaforolimusSoft tissue or bone sarcoma6/6/2012CRL
EBS21.4528.4818.28BioThraxAnthrax Vaccine5/17/2012ApprovedApproved May 17 2012
TLON0.161.830.13MarqiboPhiladelphia chromosome-negative acute lymphoblastic leukemia 5/13/2012Extended
ALXA2.275.931.99ADASUVESchizophrenia5/3/2012CRL
PLX2.295.302.05Taliglucerase alfa Gaucher disease5/1/2012Approved
VVUS3.4110.293.13AvanafilErectile dysfunction4/29/2012Approved
PGNX4.727.453.10Subcutaneous RELISTORChronic pain4/27/2012ExtendedPrice shown is for PGNX
FURX104.77121.9732.05AlogliptinDiabetes - Type 24/25/2012CRL
VVUS3.4110.293.13QnexaObesity4/17/2012Extended
CHTPNORTHERA Neurogenic Orthostatic Hypotension3/28/2012CRLAcquired by Lundbeck
AFFY0.121.210.09PeginesatideAnemia in chronic renal failure (CRF)3/27/2012ApprovedBankrupt
MAPPLevadexMigraine3/26/2012CRLAcquired by Allergan
CRIS1.324.431.19VismodegibBasal Cell Carcinoma3/8/2012ApprovedEarly decision Jan 30,2012
NGSX0.000.020.00QutenzaNeuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN)3/7/2012CRL
DSCO1.932.771.51Surfaxin Respiratory Distress Syndrome - Severe3/6/2012Approved
ASTXDacogenAcute myeloid leukemia3/6/2012CRLAcquired by Otsuka
CBRX5.807.505.30Progesterone vaginal gelReduction of risk of preterm birth2/26/2012CRL
CORT3.034.491.60Corlux - KorlymCushing's Syndrome2/17/2012Approved
BPAXBio-T-GelMale hypogonadism2/14/2012ApprovedMerged. New ticker ANIP
ALXA2.275.931.99ADASUVESchizophrenia2/4/2012Extended 3months
AMLNBYDUREONType 2 diabetes1/28/2012ApprovedAcquired by Bristol-Myers Squibb
ALKS45.9154.2534.28BYDUREONType 2 diabetes1/28/2012Approved
PLX2.295.302.05Taliglucerase alfa Gaucher disease1/2/2012Extended 3 monthsInformed Dec 6 2011
NEOLSUBSYSCancer pain1/1/2012ApprovedNew ticker INSY
AIS2.03142.70128.00AnturolOveractive bladder12/8/2011ApprovedChanged ticker to ATRS
INCY55.0770.8635.21JakafiMyelofibrosis12/3/2011ApprovedApproved Nov 16 2011
TSPT1.753.901.55IntermezzoInsomnia11/27/2011Approved
SPPI7.7010.326.36Removal of the Bioscan Requirement for ZevalinNon-Hodgkin's lymphoma11/20/2011Approved
ALIM6.02ILUVIENDiabetic macular edema11/12/2011CRLEarly CRL. Price shown is for ALIM
IGXT0.391.180.37CPI-300Major Depressive Disorder11/10/2011Approved
PCRX106.44109.9445.68EXPARELPostsurgical pain10/28/2011Approved
SGEN35.9555.9930.80ADCETRISHodgkin lymphoma8/30/2011Approved
SGEN35.9555.9930.80ADCETRISAnaplastic large cell lymphoma8/30/2011Approved
PATHZelrixMigraine8/29/2011CRLAcquired by TEVA.
MSTX0.531.100.40ExelbineNSCLC8/9/2011CRLNew ticker MSTX. Formerly ANX
TSPT1.753.901.55IntermezzoInsomnia7/14/2011CRL
PTIE4.156.223.40REMOXYModerate to severe pain6/23/2011CRL
FCSC2.956.302.60LavivWrinkles6/22/2011Approved
ACUR0.592.120.57OxectaPain relief6/17/2011Approved
OPTRFidaxomicinCDI - diarrhea5/30/2011Approved
SPPI7.7010.326.36FUSILEVColorectal cancer4/29/2011Approved
XNPT6.727.203.14HorizantRestless Legs Syndrome4/6/2011Approved
HGSI0.00BENLYSTALupus3/10/2011Approved
PLX2.295.302.05Taliglucerase alfa Gaucher disease2/25/2011CRL
OREX4.397.823.11ContraveObesity1/31/2011CRL
DEPO15.1015.707.09GRALISEPostherpetic neuralgia - shingles1/30/2011Approved
MNKD5.7311.483.80AfrezzaInsulin1/26/2011CRLEarly CRL
CLDA#N/AViibrydMajor depressive disorder1/23/2011ApprovedAcquired by Forest Laboratories (FRX)
PSDV/ALIM#N/AILUVIENDiabetic macular edema12/29/2010CRLEarly CRL. Price shown is for ALIM
CADX0.00OFIRMEVPain and fever11/4/2010Approved
BIOD1.543.711.20VIAjectDiabetes10/30/2010CRL
AVNR11.8513.092.62NUEDEXTAPseudobulbar affect10/30/2010Approved
VVUS3.4110.293.13QnexaObesity10/28/2010CRL
ALKS/AMLN#N/ABYDUREONType 2 diabetes10/22/2010CRL
ISTA0.00BROMDAYPostoperative inflammation and reduction of ocular pain10/16/2010ApprovedAcquired by Bausch + Lomb
QCOR0.0097.8047.71ActharInfantile spasms10/15/2010Approved
ALXA2.275.931.99ADASUVESchizophrenia10/11/2010CRL
JAZZ166.46176.6088.91JZP-6Fibromyalgia10/11/2010CRL
HGSIZALBINHepatitis C10/5/2010CRLAcquired by GSK
PGNX4.727.453.10RelistorOpioid-induced constipation (OIC)9/29/2010Approved
SVNTKRYSTEXXAGout9/14/2010ApprovedBankrupt
QCOR0.0097.8047.71ActharInfantile spasms6/11/2010Extended 4 months
POZN8.759.905.35VIMOVOGastric ulcers4/30/2010Approved
ITMN73.8974.2410.95EsbrietIdiopathic pulmonary fibrosis 4/5/2010CRL
SLXP140.42172.9870.64XIFAXANHepatic encephalopathy3/24/2010Approved
CTIC2.404.251.60PixuvriNon-Hodgkin's lymphoma3/23/2010CRL
SOMX3.005.441.29SilenorInsomnia3/19/2010Approved
APPA7.93APF530Chemotherapy-induced nausea and vomiting3/18/2010CRLChanged ticker to HRTX
SUPG0.00DacogenMyelodysplastic syndromes3/8/2010ApprovedChanged ticker to ASTX
ALKS45.91BYDUREONType 2 diabetes3/5/2010CRLPrice shown is for ALKS
CRXXExalgoModerate to severe pain in opioid tolerant patients3/2/2010ApprovedChanged ticker to ZLCS
CADXOFIRMEVPain and fever2/12/2010CRL
DDSS#N/AOleptroMajor depressive disorder2/11/2010ApprovedBankrupt
XNPT6.727.203.14HorizantRestless Legs Syndrome2/9/2010CRL
PLX2.295.302.05Taliglucerase alfa Gaucher disease2/9/2010Extended
ACOR34.2539.9427.51AMPYRAImprove walking in patients with multiple sclerosis1/22/2010Approved
MNKD5.7311.483.80AFREZZADiabetes1/16/2010CRLFDA responded 15 Mar 2010
FCSC2.956.302.60LavivWrinkles1/4/2010CRLEarly CRL
VIONOnriginAcute myeloid leukemia12/12/2009CRLBankrupt
SOMX3.005.441.29SilenorInsomnia12/4/2009CRL
SNTSZEGERIDGERD12/4/2009ApprovedAcquired by Salix.
DYAX10.8111.016.05KALBITORHereditary angioedema 12/1/2009Approved
NGSX0.020.00QutenzaPostherpetic neuralgia11/16/2009Approved
CADXOFIRMEVMild to moderate pain11/13/2009Approved
NRIFF4.695.201.54PennsaidOsteoarthritis of the knee11/4/2009Approved
TSPT1.753.901.55IntermezzoInsomnia11/2/2009CRL
GTXI0.622.350.41ToremifeneReduce fractures in men with prostate cancer10/30/2009CRL
SPPI7.7010.326.36FUSILEVColorectal cancer10/8/2009CRL
ALTH#N/A#N/AFOLOTYNPeripheral T-cell lymphoma9/24/2009Approved
ISTABepreveAllergic conjunctivitis9/14/2009ApprovedAcquired by Bausch + Lomb
SPPI7.7010.326.36ZEVALINNon-Hodgkin's Lymphoma 9/7/2009Approved
NGSX0.000.020.00QutenzaPostherpetic neuralgia8/17/2009Extended 3 months
SVNTKRYSTEXXAGout8/3/2009CRLBankrupt
DDSS#N/AOleptroMajor depressive disorder7/20/2009CRLBankrupt
ZGNX1.275.191.07SumavelMigraine7/15/2009Approved
ARDM8.30SumavelMigraine7/15/2009Approved
SPPI7.7010.326.36ZEVALINNHL7/2/2009CRL
HEB0.280.550.19AmpligenChronic fatigue syndrome5/25/2009CRLCRL PR released Dec 1, 2009. PDUFA date was May 25, 2009. FDA advised only of a 1-2 week delay

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.

2 Responses to “FDA Historical Calendar”

  1. Chirag says:

    a thousand thanks !!

Leave a Reply